BNP Paribas Arbitrage SA increased its position in shares of Shire PLC (NASDAQ:SHPG) by 93.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,674 shares of the biopharmaceutical company’s stock after acquiring an additional 5,149 shares during the quarter. BNP Paribas Arbitrage SA’s holdings in Shire were worth $1,635,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently bought and sold shares of SHPG. Janus Henderson Group PLC raised its stake in shares of Shire by 22,560.3% during the 2nd quarter. Janus Henderson Group PLC now owns 1,286,881 shares of the biopharmaceutical company’s stock worth $212,683,000 after acquiring an additional 1,281,202 shares in the last quarter. Glenview Capital Management LLC raised its stake in shares of Shire by 69.7% during the 2nd quarter. Glenview Capital Management LLC now owns 1,722,977 shares of the biopharmaceutical company’s stock worth $284,756,000 after acquiring an additional 707,500 shares in the last quarter. Northern Trust Corp grew its position in Shire by 45.5% during the 2nd quarter. Northern Trust Corp now owns 1,307,339 shares of the biopharmaceutical company’s stock worth $216,064,000 after purchasing an additional 408,843 shares during the last quarter. OZ Management LP purchased a new stake in Shire during the 2nd quarter worth approximately $57,614,000. Finally, Maverick Capital Ltd. grew its position in Shire by 19.9% during the 2nd quarter. Maverick Capital Ltd. now owns 1,942,087 shares of the biopharmaceutical company’s stock worth $320,969,000 after purchasing an additional 322,610 shares during the last quarter. Hedge funds and other institutional investors own 18.64% of the company’s stock.
SHPG has been the topic of several research analyst reports. Zacks Investment Research raised shares of Shire from a “sell” rating to a “hold” rating in a research report on Friday, October 27th. ValuEngine downgraded shares of Shire from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Cowen Inc set a $225.00 target price on shares of Shire and gave the stock a “buy” rating in a research report on Sunday, October 29th. Cantor Fitzgerald reissued a “buy” rating and set a $222.00 target price on shares of Shire in a research report on Thursday, September 14th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $245.00 target price on shares of Shire in a research report on Sunday, October 8th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and eleven have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $212.18.
Shares of Shire PLC (NASDAQ SHPG) opened at $147.86 on Friday. The company has a market cap of $44,421.14, a price-to-earnings ratio of 10.17, a PEG ratio of 0.82 and a beta of 1.60. The company has a quick ratio of 0.52, a current ratio of 0.98 and a debt-to-equity ratio of 0.55. Shire PLC has a twelve month low of $137.17 and a twelve month high of $192.15.
Shire (NASDAQ:SHPG) last released its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.81 EPS for the quarter, beating the consensus estimate of $3.64 by $0.17. The business had revenue of $3.70 billion for the quarter. Shire had a net margin of 10.95% and a return on equity of 14.41%. The firm’s revenue was up 7.1% on a year-over-year basis. During the same period last year, the company earned $3.17 earnings per share. sell-side analysts predict that Shire PLC will post 15 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was first posted by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at https://transcriptdaily.com/2017/11/26/shire-plc-shpg-position-lifted-by-bnp-paribas-arbitrage-sa.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.